MedComm,
Journal Year:
2025,
Volume and Issue:
6(3)
Published: March 1, 2025
The
rising
trend
in
global
cancer
incidence
has
caused
widespread
concern,
one
of
the
main
reasons
being
aging
population.
Statistical
data
show
that
and
mortality
rates
a
clear
upward
with
age.
Although
there
is
commonality
between
dysregulated
nutrient
sensing,
which
features
aging,
metabolic
reprogramming
tumor
cells,
specific
regulatory
relationship
not
clear.
This
manuscript
intends
to
comprehensively
analyze
senescence
reprogramming;
as
well
reveal
impact
key
factors
leading
cellular
on
tumorigenesis.
In
addition,
this
review
summarizes
current
intervention
strategies
targeting
sensing
pathways,
clinical
cases
treating
tumors
characteristics
existing
nanodelivery
research
strategies.
Finally,
it
also
suggests
sensible
dietary
habits
for
those
who
wish
combat
aging.
conclusion,
attempts
sort
out
link
metabolism
provide
new
ideas
treatment.
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: May 22, 2024
L-arginine
can
produce
nitric
oxide
(NO)
under
the
action
of
inducible
synthase
(iNOS),
while
5-fluorouracil
(5-FU)
induce
increase
iNOS
expression.
The
present
study
was
to
investigate
mechanism
combined
with
5-FU
regulating
glucose
metabolism
hepatocellular
carcinoma
(HCC)
through
iNOS/NO/AKT
pathway.
combination
and
resulted
in
decreased
cell
survival
exhibited
synergistic
cytotoxic
effects
HepG2
SMMC7721
cells.
Meanwhile,
increased
inhibitory
effect
on
cells
by
increasing
NO
production.
Co-treatment
a
significant
decrease
both
G6PDH
LDH
enzymatic
activities,
as
well
reduced
levels
ATP
LD
compared
treatment
or
alone.
Moreover,
expression
GLUT1,
PKM2,
LDHA,
p-PI3K
p-AKT.
Furthermore,
demonstrated
downregulating
HIF-1α
β-catenin,
which
were
further
diminished
upon
addition
shikonin,
specific
inhibitor
PKM2.
LY294002
LDHA
proteins
induced
group.
However,
reduction
p-PI3K,
p-AKT,
GLUT1
caused
also
reversed
knockdown,
respectively.
Additionally,
led
greater
activity
ALT,
AST,
LDH,
hepatic
index,
AFP,
AFP-L3,
rat
model
HCC.
simultaneous
administration
significantly
improved
gross
morphology
liver,
nuclear
atypia,
inhibited
proliferation
cancer
cells,
Taking
together,
inhibition
enzymes
aerobic
glycolysis
via
pathway,
suppression
downregulation
transcription
factors,
thereby
impeding
Pharmaceutics,
Journal Year:
2022,
Volume and Issue:
14(8), P. 1606 - 1606
Published: Aug. 1, 2022
Clinically,
cancer
drug
resistance
to
chemotherapy,
targeted
therapy
or
immunotherapy
remains
the
main
impediment
towards
curative
therapy,
which
leads
directly
treatment
failure
along
with
extended
hospital
stays,
increased
medical
costs
and
high
mortality.
Therefore,
increasing
attention
has
been
paid
nanotechnology-based
delivery
systems
for
overcoming
in
cancer.
In
this
respect,
novel
tumor-targeting
nanomedicines
offer
fairly
effective
therapeutic
strategies
surmounting
various
limitations
of
immunotherapy,
enabling
more
precise
treatment,
convenient
monitoring
agents,
as
well
resistance,
including
multidrug
(MDR).
Nanotechnology-based
systems,
liposomes,
polymer
micelles,
nanoparticles
(NPs),
DNA
nanostructures,
enable
a
large
number
properly
designed
nanomedicines.
paper,
we
review
different
mechanisms
discuss
latest
developments
resistance.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology,
Journal Year:
2022,
Volume and Issue:
15(1)
Published: Aug. 21, 2022
Abstract
The
tumor
microenvironment
(TME)
is
a
very
cunning
system
that
enables
cells
to
escape
death
post‐traditional
antitumor
treatments
through
the
comprehensive
effect
of
different
factors,
thereby
leading
drug
resistance.
Deep
insights
into
TME
characteristics
and
resistance
encourage
construction
nanomedicines
can
remodel
against
Tremendous
interest
in
combining
TME‐regulation
measurement
with
traditional
treatment
fight
multidrug‐resistant
tumors
has
been
inspired
by
increasing
understanding
role
reconstruction
improving
efficiency
drug‐resistant
therapy.
This
review
focuses
on
underlying
relationships
between
specific
(such
as
hypoxia,
acidity,
immunity,
microorganisms,
metabolism)
treatments.
exciting
activities
strengthened
regulation
are
also
discussed
in‐depth,
providing
solutions
from
perspective
nanomedicine
design.
article
categorized
under:
Therapeutic
Approaches
Drug
Discovery
>
Emerging
Technologies
Nanomedicine
for
Oncologic
Disease
Nanotechnology
Biology
Nanoscale
Systems
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Feb. 15, 2024
Background
Despite
the
introduction
of
combined
antiretroviral
therapy,
AIDS-related
diffuse
large
B-cell
lymphoma
(AR-DLBCL)
remains
a
prominent
cancer
among
individuals
living
with
HIV
suboptimal
prognosis.
Identifying
independent
prognostic
markers
could
improve
risk
stratification.
Methods
In
this
multicenter
retrospective
cohort
study
spanning
years
2011
to
2019,
153
eligible
patients
AR-DLBCL
were
examined.
Overall
survival
(OS)
factors
analyzed
using
Kaplan–Meier
curves,
and
univariate
multivariate
Cox
proportional
hazards
models.
The
discriminatory
ability
score
was
evaluated
by
examining
area
under
receiver
operating
characteristic
curve.
Results
included
median
age
47
(interquartile
range
[IQR]
39–58),
83.7%
whom
men.
follow-up
12.0
months
(95%
confidence
interval
[CI],
8.5–15.5),
an
OS
rate
35.9%.
Among
potential
inflammatory
examined,
only
ratio
hemoglobin
(g/dL)
red
cell
distribution
width
(%)
(Hb/RDW)
emerged
as
parameter
for
in
training
(hazard
ratios
[HR]
=
2.645,
95%
CI
1.267–5.522,
P
0.010)
validation
cohorts
(HR
0.010).
A
lower
Hb/RDW
strongly
correlated
adverse
clinical
factors,
including
advanced
Ann
Arbor
stage,
increased
extranodal
sites,
reduced
CD4
count,
elevated
lactate
dehydrogenase
levels,
poorer
Eastern
Cooperative
Oncology
Group
performance
status
(ECOG
PS),
higher
International
Prognostic
Index
(IPI)
score.
addition
IPI
produced
highly
composite
score,
termed
Hb/RDW-IPI.
Conclusion
We
identified
cost-effective
readily
available
biomarker,
ratio,
predictor
outcomes
AR-DLBCL.
Its
integration
into
partially
improves
accuracy.
Scandinavian Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
59(6), P. 730 - 736
Published: March 1, 2024
Background
Hepatocellular
carcinoma
(HCC)
is
the
most
malignant
cancer
worldwide.
Sorafenib
(SRF)
a
common
therapeutic
drug
used
for
patients
with
advanced
HCC.
Nevertheless,
resistance
frequently
occurs
in
treated
sorafenib.
Glycyrrhizic
acid
(GRA)
natural
compound
that
identified
to
exhibit
anti-cancer
effects.
In
this
work,
we
aimed
investigate
effects
of
GRA
on
SRF-resistant
HCC
cells
and
potential
regulatory
mechanisms.
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: Aug. 22, 2022
Prior
investigations
of
the
tumor
microenvironment
(TME)
diffuse
large
B-cell
lymphoma
(DLBCL)
have
shown
that
immune
and
stromal
cells
are
key
contributing
factors
to
patients'
outcome.
However,
challenges
remain
in
finding
reliable
prognostic
biomarkers
based
on
cell
infiltration.
In
this
study,
we
attempted
shed
some
light
chemokine
C-C
motif
ligand
8
(CCL8)
DLBCL
via
interaction
with
M2
macrophages.The
Estimation
STromal
Immune
MAlignant
Tumor
tissues
using
Expression
data
(ESTIMATE)
algorithm
was
applied
evaluate
scores
from
transcriptomic
profiles
443
samples
The
Cancer
Genome
Atlas
(TCGA)
GSE10846
datasets.
infiltration
(ICI)
clusters
were
obtained
different
infiltrations
each
sample,
gene
derived
through
differentially
expressed
genes
(DEGs)
between
distinct
ICI
clusters.
Five
immune-related
hub
related
overall
survival
(OS)
clinical
stages
by
COX
regression
analysis
protein-protein
(PPI)
network
construction
then
verified
quantitative
real-time
PCR
(qPCR)
immunofluorescence
staining
FFPE
tissues.
Gene
Ontology
(GO),
Kyoto
Encyclopedia
Genes
Genomes
(KEGG),
TIMER
websites
employed
explore
biological
functions
CCL8-related
DEGs.
Uni-
multivariable
Cox
analyses
performed
analyze
CCL8
as
an
independent
risk
factor
other
GEO
cohorts.A
higher
score
associated
favorable
prognosis
DLBCL.
Patients
B
cluster
had
a
better
follow-up
status
programmed
death
1
(PD-L1)
cytotoxic
T-lymphocyte
antigen
4
(CTLA4)
expression.
Most
ICI-related
DEGs
enriched
for
signaling
pathways.
association
identified,
including
CD163,
which
is
biomarker
macrophages,
CCL8.
Abundant
macrophages
discovered
high-CCL8
expression
group.
functional
indicated
component
processes
secretory
granule
groups.
GSE
datasets
yielded
additional
evidence
value
DLBCL.CCL8
has
been
implicated
macrophage
recruitment
several
solid
tumors,
only
few
reports
published
role
pathogenesis
hematological
malignancies.
This
article
find
out
TME-related
patients.
identified
be
involved
activities.
Importantly,
series
bioinformatics
might
become
effective
target
DLBCL,
interacts
checkpoint.
potential
mechanisms
need
further
elucidated.
MedComm,
Journal Year:
2023,
Volume and Issue:
4(5)
Published: Aug. 24, 2023
Drug
resistance
remains
the
greatest
challenge
in
improving
outcomes
for
cancer
patients
who
receive
chemotherapy
and
targeted
therapy.
Surmounting
evidence
suggests
that
a
subpopulation
of
cells
could
escape
intense
selective
drug
treatment
by
entering
drug-tolerant
state
without
genetic
variations.
These
(DTCs)
are
characterized
with
slow
proliferation
rate
reversible
phenotype.
They
reside
tumor
region
may
serve
as
reservoir
resistant
phenotypes.
The
survival
DTCs
is
regulated
epigenetic
modifications,
transcriptional
regulation,
mRNA
translation
remodeling,
metabolic
changes,
antiapoptosis,
interactions
microenvironment,
activation
signaling
pathways.
Thus,
targeting
regulators
opens
new
avenue
therapy-resistant
tumors.
In
this
review,
we
first
provide
an
overview
common
characteristics
regulating
networks
development.
We
also
discuss
potential
therapeutic
opportunities
to
target
DTCs.
Last,
current
challenges
prospects
DTC-targeting
approach
overcome
acquired
resistance.
Reviewing
latest
developments
DTC
research
be
essential
discovering
methods
eliminate
DTCs,
which
represent
novel
strategy
preventing
future.
Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
170, P. 116021 - 116021
Published: Dec. 20, 2023
Hepatocellular
carcinoma
(HCC)
poses
a
heavy
burden
on
human
health
with
high
morbidity
and
mortality
rates.
Systematic
therapy
is
crucial
for
advanced
mid-term
HCC,
but
faces
significant
challenge
from
therapeutic
resistance,
weakening
drug
effectiveness.
Metabolic
reprogramming
has
gained
attention
as
key
contributor
to
resistance.
Cells
change
their
metabolism
meet
energy
demands,
adapt
growth
needs,
or
resist
environmental
pressures.
Understanding
enzyme
expression
patterns
metabolic
pathway
interactions
vital
comprehend
HCC
occurrence,
development,
treatment
Exploring
pathways
essential
identify
breakthrough
points
treatment.
Targeting
enzymes
inhibitors
addressing
these
points.
Inhibitors,
combined
systemic
drugs,
can
alleviate
prolong
overall
survival
offer
patients
chance
radical
resection.
Advances
in
research
methods,
genomics
metabolomics
cells
organoids,
help
build
the
network.
Recent
progress
biomaterials
nanotechnology
impacts
targeting
effectiveness,
providing
new
solutions
This
review
focuses
changes,
interactions,
inhibitors,
delivery
reprogramming,
offering
valuable
references
approaches
